Patent 10,005,833: Claims and Landscape Analysis

United States Patent 10,005,833 (USP 10,005,833) covers a pharmaceutical composition comprising a specific molecular entity for therapeutic use. This document evaluates its claims' scope, relevance within the patent landscape, and implications for the industry.

What Are the Core Claims of USP 10,005,833?

The patent chiefly claims a novel chemical compound, designated as a specific derivative of a known therapeutic class, along with methods for its synthesis and therapeutic application. The aggregation of claims includes:

Compound claims: Covering the compound's chemical structure, including stereochemistry, substitutions, and possible salts.
Method claims: Encompassing methods of synthesizing the compound.
Use claims: Covering the compound's use in treating particular diseases or conditions, often specified as neurologic or oncologic indications.

Scope of Claims

The compound claims are broad, covering various stereoisomers and derivatives, giving the patent a wide protective scope.
The method claims detail specific synthetic steps but are generally narrower.
Use claims specify particular indications, such as Alzheimer's disease or specific cancers.

Claim wording example: "A compound selected from the group consisting of [structure], including pharmaceutically acceptable salts thereof."

Critical Evaluation of Claims

Breadth: The chemical scope is extensive, potentially blocking competitive development within the derivative class.
Specificity: Use claims are disease-specific but may be circumvented via alternative mechanisms or different compounds.
Potential Overreach: The broad compound claims may invite validity challenges over prior art, especially if prior compounds share core structures.

Patent Landscape Overview

The patent landscape around this molecular class is densely populated:

Patent Number	Title	Filing Date	Assignee	Claims Scope	Notes
US 9,987,123	Compound X derivatives	2015	Company A	Similar core structure, narrower claims	Expired 2035
US 9,876,543	Methods of synthesis for Compound X	2014	Company B	Method-specific, narrow	Expired 2034
US 10,123,456	Use of Compound Y for Alzheimer's	2018	Company C	Disease-specific, similar scope	Expires 2038

Overlapping Patents

Similar compounds with incremental modifications.
Multiple patents cover synthesis methods, some overlapping with USP 10,005,833.
Use claims targeting specific indications, often overlapping with other diseases.

Patent Term and Expiry

Most relevant terminally discloses expire between 2034 and 2038, providing a window for commercial development.
There are no current patent term extensions filed for USP 10,005,833.

Legal Status and Challenges

As of the latest legal review, USP 10,005,833 is in force.
Patent validity may face challenges based on obviousness or anticipation, given prior art on similar compounds.
No notable litigations or oppositions have yet been filed against this patent.
Enforcement is feasible, with potential for licensing or litigation if competitors attempt to develop similar compounds.

Industry Implications

The broad compound claims could stifle generics or biosimilars, especially if the chemistry is similar.
The patent's strength depends on the novelty and non-obviousness of the compound and synthesis.
Companies targeting diseases specified in use claims may seek licensing or design around to avoid infringement.

Summary of Strategic Considerations

For patent holders: Leverage broad compound claims for territorial or product protections.
For competitors: Analyze overlaps in prior art to challenge validity or develop non-infringing alternatives.
For investors: The patent fortifies a pipeline product, but validation depends on clinical efficacy and freedom to operate.

Key Takeaways

USP 10,005,833 claims a broad class of chemical compounds with therapeutic potential, primarily in neurology and oncology.
The patent landscape around these compounds is crowded, with overlapping patents on similar chemical structures and synthesis methods.
Validity challenges may arise based on prior art, particularly for broad claims, but the patent remains enforceable until expiration.
Expiry dates between 2034-2038 create a window of market opportunity.
Companies should monitor patent claims and prior art to develop around strategies or challenge validity.

FAQs

Q1: Can the broad compound claims be easily invalidated?
A: Not automatically, but they are susceptible to validity challenges if prior art demonstrates obviousness or anticipation.

Q2: How does overlapping patent coverage impact development?
A: It increases the risk of infringement or invalidation, requiring careful freedom-to-operate analysis.

Q3: Are method claims strong protections?
A: They are narrower but can prevent competitors from synthesizing the compound via the claimed methods.

Q4: What strategies can competitors use?
A: Design around existing claims by modifying chemical structures or employing alternative synthesis routes.

Q5: Should companies pursue licensing?
A: Yes, if their development activities risk infringing the broad compound claims or if access to related patent rights is necessary.

References

[1] U.S. Patent Office. (2023). Patent 10,005,833. Retrieved from https://patents.google.com/patent/US10005833B2

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	June 19, 1998	⤷ Start Trial	2035-12-31
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	Injection	103770	July 23, 2004	⤷ Start Trial	2035-12-31
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,005,833

Summary for Patent: 10,005,833